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Uremia-associated immune defect: The IL-10–CRP axis. Un- remains controversial if these factors are also pathoge-
stable atherosclerotic disease is related to systemic inflamma- netically involved in the process of the rapidly devel-
tion. While this inflammation remains at a subclinical level in
oping and progressing atherosclerosis in ESRD patients.otherwise healthy individuals, chronic elevation of pro-in-
flammatory cytokines is a common feature in patients with
end-stage renal disease (ESRD). Current hypotheses on the
pathogenetic links between inflammation and atherosclerosis A CELLULAR APPROACH TO
emphasize that cytokine-producing monocytes/macrophages INFLAMMATION IN THE DIALYSIS PATIENT
can actively infiltrate atherosclerotic plaques. A high activation
We proposed a cell-based approach to inflammationlevel of this cell type may contribute to plaque growth.
In the healthy, some 15% to 20% of circulating monocytes in chronic renal failure. Circulating monocytes, or their
may be activated for cytokine production. This percentage is descendants, the macrophages, mainly secrete the pro-much higher in dialysis patients (50%), which may contribute
inflammatory cytokines cited above. Although secretionto the rapid progression of atherosclerosis. Anti-inflammatory
mechanisms such as interleukin-10 (IL-10) limit the production by lymphocytes is possible as well, this probably does
of a broad range of pro-inflammatory factors. Animal models, not play a major role in ESRD, since the known aspects
as well as clinical findings, suggest an involvement of this cyto- of immune activation in these patients seem not to bekine in the pathogenesis of vascular lesions. In hemodialysis
antigen specific. The activation state of circulating mono-(HD) patients, a protective role of IL-10 against systemic in-
flammation could be proven. cytes can be measured by means of the cytoflow tech-
A high interindividual variability in IL-10 production leads nique, a single-cell detection of cytokine production in
to distinct patient groups who can or cannot effectively limit the
monocytes [1]. This technique revealed that only 15%uremia- and dialysis-induced inflammation. Single nucleotide
to 20% of the circulating monocytes in the healthy arepolymorphisms (SNPs) in the promotor of the IL-10 gene may
genetically explain this heterogeneity. The IL-10 genotype capable of cytokine production, even after stimulation by
strongly influences the range of variation of C-reactive protein endotoxin. In contrast, some 50% of circulating mono-
(CRP), the most widely used marker of inflammation in dialysis
cytes in HD patients secrete IL-6. The amount of thispatients. By limiting the inflammatory activation in ESRD pa-
tients, the IL-10 genotype is predictive for the risk of cardiovas- pro-inflammatory cytokine per single cell was not ele-
cular disease, meaning that the IL-10 “high-producer” geno- vated in ESRD patients (Fig. 1). Monocytes and macro-
type is associated with a lower event rate, and even mortality, phages are important constituents of the atheroscleroticthan the IL-10 “low-producer” genotype.
plaque. They are particularly related to plaque growth
and instabilization. Cytokines and chemotactic factors
produced by macrophages attract further leukocytes intoChronic systemic inflammation in ESRD patients has
the lesion. Proteolytic enzymes, such as matrix metallo-been documented in a wide array of clinical and experi-
proteinases secreted by these cells, induce digestion ofmental studies. The causes of inflammation are partly
the fibrous cap of a plaque, thus the breaking in towardunderstood and include uremia, as well as renal replace-
ment therapy. C-reactive protein in plasma and several the vascular lumen. This induces thrombocyte adhesion
pro-inflammatory cytokines, such as IL-1, tumor necro- and occlusion of the vessel, leading to the vascular catas-
sis factor-alpha, and IL-6, are used to detect the inflam- trophe [2]. The presence of macrophages and the expres-
matory state. These markers are circulating factors that sion of cytokines within the atherosclerotic plaque is well
reflect an activation of the immune system. However, it documented [3, 4]. A high prevalence of atherosclerotic
disease has also been shown for chronic systemic in-
flammation of causes other than ESRD, as found inKey words: interleukin-10, hemodialysis, atherosclerosis, chronic kid-
ney failure. chronic respiratory, urinary tract, or dental infection [5].
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production. At least one third of all individuals seems
to be unable to enhance the production of IL-10 in a
sufficient way to get control of the overwhelming in-
flammation in ESRD.
THE ROLE OF IL-10 IN
ATHEROSCLEROTIC DISEASE
Several lines of evidence indicate a pathogenetic role
Fig. 1. Elevated circulating numbers of monocytes that may be acti- for IL-10 in atherosclerotic disease. First, animal experi-vated for the production of IL-6 in dialysis patients. Blood was drawn
ments show that IL-10 can limit the progression of exper-prior to dialysis from ESRD patients and healthy controls. Leukocytes
were incubated with lipopolysaccharide (LPS), and subsequently stained imental atherosclerosis. IL-10–deficient knockout mice
for intracellularly accumulated cytokines. The fraction of cytokine posi- have a thirtyfold increase in susceptibility to atheroscle-tive cells was compared using flow cytometry. There were more than
rosis, due to high cholesterol diet [9], or in a cardiactwice as many circulating monocytes with the capability of inflammatory
action in dialysis patients compared to controls [1]. allograft vasculopathy setting [10]. The transfection of
adenovirus-mediated overexpression of IL-10 into the
LDL-receptor knockout mouse strongly inhibits the oth-
erwise rapidly growing atherosclerotic lesions in theseESRD patients may be an important risk factor for the
animals [11]. Furthermore, IL-10 also plays a role inprogression of atherosclerosis in this patient group. It is
human coronary artery disease. A study compared 50likely that this finding is more closely related to the
patients with stable and 45 patients with unstable anginapathogenesis of the vascular plaque than the detection
pectoris. Plasma IL-6 levels where significantly higherof the circulating activation markers of monocytes in
and plasma IL-10 levels lower in those patients with theplasma.
unstable form of the disease [12].
IL-10: THE ANTI-INFLAMMATORY CYTOKINE
THE IL-10 GENOTYPE IS PREDICTIVE FORIn the healthy, inflammation is tightly controlled by
CARDIOVASCULAR EVENTSanti-inflammatory mechanisms. While inflammation, with
The IL-10 gene shows single nucleotide polymor-its tissue-destructive effects, is necessary for the elimina-
phisms (SNPs) that are related to the secretion rate oftion of pathogens, it needs to be limited after the immune
the cytokine [13]. These SNPs are found at positionsreaction has been successful. IL-10 is one of the most
–1082, –819, and –592, upstream of the coding sequence.important factors to limit, and finally shut down, the in-
The different genotypes are equally distributed withinflammatory response [6]. IL-10 is produced by the same
the Caucasian population. We recently confirmed in HDcell types, mainly monocytes and lymphocytes, which
patients that the –1082 polymorphism determines a dif-secrete pro-inflammatory factors. Its secretion follows
ferent amount of IL-10 upon a certain stimulus [14].the same stimuli, but with different kinetics. A six- to
Homozygous carriers of the –1082 G allele show a 30%eight-hour delay physiologically opens a time window
higher secretion of IL-10 compared with homozygousfor the effects of pro-inflammatory factors before they
carriers of the –1082 A allele. This leads to a betterare transcriptionally down regulated again.
inflammation control in the IL-10 “high-producer” pa-IL-10 is also an important cytokine in patients with
tients than the “low-producer” patients. As expected,ESRD. Several studies observed elevated levels of IL-10
heterozygous patients were in between both groups of[7, 8], and the substance was proven to be effective in
patients. Inflammation control was determined by athese patients, as well. Nevertheless, higher levels of
scheduled detection of CRP at six predefined datesIL-10 are needed in comparison with healthy persons
within a 6-month period, regardless of whether the pa-to limit the strong inflammatory activation of ESRD
tient had intercurrent complications or not. Patients withpatients. In light of these findings, the elevation of IL-10
the IL-10 “high-producer” genotype had significantlyseems to be a counter-regulatory mechanism to control
less variation and less elevation of CRP levels (meanuremia- and dialysis-induced activation.
over 6 months, 17 patients: 8.4  1.7 mg/L) than thoseBy using single-cell cytokine measurements, the mech-
with the IL-10 “low-producer” genotype (26 patients,anism by which the immune system enhances the produc-
18.2  1.6 mg/L, P  0.01). This might be understood astion of IL-10 could be uncovered. In contrast to IL-6,
a “permissive effect” of the IL-10 genotype for systemicwhich is derived from a higher number of cytokine-pro-
inflammation: inflammatory mediators are induced in allducing cells, a higher level of secretion per single cell
patients with chronic renal failure due to uremia and(Fig. 1) [1] mainly enhances IL-10 secretion. There is
a wide interindividual variation in the levels of IL-10 renal replacement therapy. However, while those with
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Fig. 2. The interleukin-10 hypothesis linking
dialysis-associated inflammation, the IL-10 ge-
notype, and the cardiovascular prognosis in
dialysis patients.
the IL-10 “high-producer” genotype may effectively limit disease [16], the levels of inflammation are more than
tenfold different. Thus, it is not surprising that two stud-inflammation, this is not the case in the “low-producer”
group (Fig. 2). ies of the IL-10 genotype in patients with normal renal
function did not detect a relation to myocardial in-Effective control of chronic systemic inflammation
should be associated with a lower risk of cardiovascular farction [17] or unstable angina [18]. The IL-10 genotype
is a marker for the risk of an individual patient withdisease in dialysis patients. Therefore, we conducted a
multi-center prospective observational study that in- ESRD to develop progression of atherosclerotic disease.
This parameter should be taken into account for futurecluded 300 chronic HD patients [15]. These patients were
followed over 20.2  7.3 months for cardiovascular clinical studies in this field since it allows for the defini-
tion of much more homogenous patient groups. Inter-events and mortality. Stratification for the IL-10 –1082
polymorphism revealed a significantly higher risk both vention should first focus on patients homozygous for
the IL-10 “low-producer” genotype since they may havefor events and cardiovascular mortality in patients with
the IL-10 “low-producer” genotype. These data impres- the largest benefit. Potential interventions are the use
sively confirm the important role of IL-10 for the protec- of thrombocyte inhibitors such as clopidogrel or HMG-
tion of the individual against the long-term effects of CoA reductase inhibitors. The latter have strong anti-
chronic systemic inflammation. inflammatory effects besides their lipid-lowering action.
Several groups recently embarked on studying gene A recent study already used markers of inflammation to
polymorphisms and their association with mortality in direct a statin therapy, and could show a benefit in pri-
dialysis patients. However, interpretation of such data mary prevention of cardiovascular disease [19].
needs to take several weaknesses of these studies into
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